Abstract
800x600 Background: Endometrioid endometrial adenocarcinoma is the most frequent in menopause. Although we think that patients with this carcinoma has good prognosis, 25% with diagnosed FIGO stage I have 5 years survival rate since moment of diagnosis. Aim of this study was to correlate FIGO stages Ib and Ia with age, hypertension, diabetes mellitus and obesity in endometrioid endometrial adenocarcinoma, histological grad 2. Methods: In retrospective study we observed patients who were admitted for operative treatment of endometrioid endometrial adenocarcinoma, histological grad 2 in period 1995 to 2006 at Ob/Gyn Clinic Tuzla. We analyzed 30 patients in observed group (FIGO stage Ib) and 30 patients in control group (FIGO stage Ia). Results: Average age of the patients in observed group was 61,26 and in control group was 54,36. Using t-test we found statistically significant difference of average age in observed and control group (t=3.349, P=0.001). With Fisher test we found that chance for finding diabetes mellitus in observed group was 9,67 times higher (95%CI: 1.07- 450.31). Conclusion: In our study we found that FIGO stages Ib and Ia of endometrioid endometrial adenocarcinoma, pathological grad 2 are age dependent and that presence of diabetes mellitus was 9,67 times higher in FIGO stage Ib than in Ia. Considering this founding we should recommend radical treatment with adjuvant therapy in cases of patients older than 56 or if their reproductive age is higher than 38 years and if they have diabetes mellitus regardless of depth of myometrial invasion. Normal 0 21 false false false BS-LATN-BA X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:Table Normal; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:Calibri,sans-serif;}
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.